scholarly journals Therapeutic effect of Northern Labrador tea extracts for acute myeloid leukemia

2018 ◽  
Vol 32 (8) ◽  
pp. 1636-1641 ◽  
Author(s):  
Colin M. McGill ◽  
Patrick L. Tomco ◽  
Regina M. Ondrasik ◽  
Kaitlyn C. Belknap ◽  
Gaelen K. Dwyer ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Therapeutic Effect ◽  
Myeloid Leukemia ◽  
Labrador Tea ◽  
Acute Myeloid

scholarly journals Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles

2017 ◽  
Vol 16 (6) ◽  
pp. 1031-1040 ◽  
Author(s):  
Nicolas Floc'h ◽  
Susan Ashton ◽  
Paula Taylor ◽  
Dawn Trueman ◽  
Emily Harris ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Therapeutic Effect ◽  
Myeloid Leukemia ◽  
Aurora B ◽  
Acute Myeloid

Application and Analysis of 6-Mercaptopurine Nanomedicine in the Treatment of Leukemia

2021 ◽  
Vol 21 (2) ◽  
pp. 1001-1007
Author(s):  
Xueying Lu ◽  
Yandong Xie ◽  
Fengyu Wang
Keyword(s):  
Acute Myeloid Leukemia ◽  
Hyaluronic Acid ◽  
Side Effects ◽  
Therapeutic Effect ◽  
Targeted Delivery ◽  
Myeloid Leukemia ◽  
Water Solubility ◽  
Drug Loading ◽  
Circulation Time ◽  
Acute Myeloid

As a first-line drug widely used in the treatment of leukemia, 6-MP has obvious effects on leukemia. However, 6-MP disadvantages such as poor solubility in water, easy binding with serum proteins, short circulation time, and large toxic and side effects greatly limit the application of 6-MP. For this reason, various 6-MP nano drug-loading systems have been designed to increase the water solubility of 6-MP, extend the circulation time, and increase the bioavailability of 6-MP to a certain extent, reducing its toxic and side effects. However, its therapeutic effect in vivo and in vitro is still far from expectations, and there is a lot of room for improvement. In order to solve the above problems encountered in the clinical application of 6-MP, we have tried two ways of polymer prodrugs and drug-loaded vesicles to achieve efficient targeted delivery and treatment of 6-MP. We designed hyaluronic acid (HA)-based gluteal-skin-responsive 6-MP polymer prodrug (HA-GS-MP) for highly effective targeted therapy of acute myeloid leukemia. Hyaluronic acid is a natural polysaccharide, which has excellent biocompatibility and biodegradability, and has a good ability to actively target malignant tumor cells overexpressing the CD44 receptor. 6-MP is connected to the HA chain through a vinyl sulfide bond, which is stable under physiological conditions (no drug release), and under intracellular reducing conditions, the connection bond is broken and 6-MP is quickly released. HA-GS-MP has a simple preparation process, good water solubility, long cycle time, and strong targeting ability. This GSH-responsive CD44 targeted 6-MP polymer prodrug is expected to improve the therapeutic effect on acute myeloid leukemia cells.

scholarly journals HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target

2020 ◽  
Vol 99 (1) ◽  
pp. 107-118
Author(s):  
Lulu Liu ◽  
Jingjing Zhang ◽  
Xianning Zhang ◽  
Panpan Cheng ◽  
Lei Liu ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Acute Myeloid Leukemia ◽  
Therapeutic Effect ◽  
Therapeutic Target ◽  
Myeloid Leukemia ◽  
Myeloid Differentiation ◽  
List Type ◽  
Promising Therapeutic Target ◽  
Hmgb1 Expression ◽  
Acute Myeloid

Abstract High mobility group box 1 (HMGB1) is a non-histone nuclear protein which has been intensively studied in various physiological and pathological processes including leukemia. Here in this study, we further demonstrated that HMGB1 presents higher expression in the bone marrow mononuclear cells of acute myeloid leukemia (AML) patients compared with the normal controls and contributes to the AML pathogenesis and progression by inhibiting apoptosis, facilitating proliferation, and inducing myeloid differentiation blockade of AML cells. Mechanistic investigation revealed that transforming growth factor beta-induced (TGFBI) acts as a potential downstream target of HMGB1 and lentivirus-mediated knockdown of TGFBI expression impaired phorbol-12-myristate-13-acetate (PMA) and all-trans retinoic acid (ATRA)–induced myeloid differentiation of AML cell lines. On the other hand, chidamide, an orally histone deacetylase inhibitor, decreases HMGB1 expression significantly in AML cells with concomitant upregulation of TGFBI expression, and confers therapeutic effect on AML by inducing cell differentiation, apoptosis and inhibiting cell proliferation. In conclusion, our findings provide additional insights that HMGB1 is a promising therapeutic target of AML, and also present experimental evidence for the clinical application of chidamide as a novel agent in AML therapy by downregulating HMGB1 expression. Key messages HMGB1 induces cell proliferation and myeloid differentiation blockade and inhibits apoptosis of AML cells. TGFBI acts as a potential target of HMGB1. Chidamide, a selective HDAC inhibitor, confers promising therapeutic effect for AML via downregulating HMGB1 expression.

scholarly journals Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1127
Author(s):  
Morgann Klink ◽  
Mohammad Atiqur Rahman ◽  
Chunhua Song ◽  
Pavan Kumar Dhanyamraju ◽  
Melanie Ehudin ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Dna Binding ◽  
Therapeutic Effect ◽  
Therapeutic Efficacy ◽  
Myeloid Leukemia ◽  
B Cell Lymphoma ◽  
Preclinical Models ◽  
Ck2 Inhibitor ◽  
Acute Myeloid

Protein Kinase CK2 (Casein Kinase 2 or CK2) is a constitutively active serine-threonine kinase overactive in human malignancies. Increased expression and activity of CK2 in Acute Myeloid Leukemia (AML) is associated with a poor outcome. CK2 promotes AML cell survival by impinging on multiple oncogenic signaling pathways. The selective small-molecule CK2 inhibitor CX-4945 has shown in vitro cytotoxicity in AML. Here, we report that CX-4945 has a strong in vivo therapeutic effect in preclinical models of AML. The analysis of genome-wide DNA-binding and gene expression in CX-4945 treated AML cells shows that one mechanism, by which CK2 inhibition exerts a therapeutic effect in AML, involves the revival of IKAROS tumor suppressor function. CK2 phosphorylates IKAROS and disrupts IKAROS’ transcriptional activity by impairing DNA-binding and association with chromatin modifiers. Here, we demonstrate that CK2 inhibition decreases IKAROS phosphorylation and restores IKAROS binding to DNA. Further functional experiments show that IKAROS negatively regulates the transcription of anti-apoptotic genes, including BCL-XL (B cell Lymphoma like–2 like 1, BCL2L1). CX-4945 restitutes the IKAROS-mediated repression of BCL-XL in vivo and sensitizes AML cells to apoptosis. Using CX-4945, alongside the cytotoxic chemotherapeutic drug daunorubicin, augments BCL-XL suppression and AML cell apoptosis. Overall, these results establish the in vivo therapeutic efficacy of CX-4945 in AML preclinical models and determine the role of CK2 and IKAROS in regulating apoptosis in AML. Furthermore, our study provides functional and mechanistic bases for the addition of CK2 inhibitors to AML therapy.

Sign in / Sign up

Export Citation Format

Share Document